Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00535132 · ClinicalTrials.gov registry record · Phase 4
Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone
A Phase 4 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 4
- Development phase
- 201
- Enrollment target
NCT00535132 is a Phase 4 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 201 participants.
The verdict
NCT00535132, a Phase 4 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 201 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg of risperidone daily by mouth, but who are not satisfied with their treatment.
Interventions
- DRUG Paliperidone ER
- DRUG Oral Risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00535132
The ClinicalTrials.gov registry entry for NCT00535132 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Paliperidone ER is the first listed.
NCT00535132 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00535132 about?
NCT00535132 is a clinical study titled "Study to Measure Drug Satisfaction of Patients With Schizophrenia After Switching From Risperidone to Paliperidone". The purpose of this study is to evaluate medication satisfaction after at least 4 weeks of paliperidone ER (extended-release), an antipsychotic, treatment in patients with schizophrenia who were previously taking either 4 or 6 mg of risperidone daily by mouth, but who are not satisfied with their tr...
What is the current status of trial NCT00535132?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 201 participants. The study started on 2007-10. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00535132?
The interventions under investigation include: Paliperidone ER (DRUG), Oral Risperidone (DRUG).
Who is sponsoring clinical trial NCT00535132?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.